The clinical supply route for PF-06650833 has successfully supported the advancement of the program through Phase 2 studies despite numerous synthetic challenges, most notably the all <i>cis </i>stereochemistry of the lactam fragment, including an <i>α</i>-fluoro stereocenter. Significant improvements have been made on the clinical supply route through innovative chemistry and process development. The improvements not only supported greater API demands with reduced cost and lead time, but also made the route a potential commercial route.

Development towards a potential commercial route for an IRAK4 inhibitor PF-06650833

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.